H2N2V1, Main, Exploration, bibRecord, 001854

Therapeutic options for the management of influenza

Identifieur interne : 001854 ( Main/Exploration ); précédent : 001853; suivant : 001855

Therapeutic options for the management of influenza

Auteurs : Michael G. Ison [États-Unis] ; Frederick G. Hayden [États-Unis]

Source :

Current Opinion in Pharmacology [ 1471-4892 ] ; 2001.

RBID : ISTEX:E322701CE07DFA8A0DF19075A00CA8FD6F0E9CA4

Descripteurs français

Wicri :
- topic : Pharmacologie.

English descriptors

KwdEn :
- Amantadine, Influenza, M2 Inhibitor, Neuraminidase inhibitor, Oseltamivir, Pharmaceutical Science, Pharmacology, Ribavirin, Rimantadine, Virology, Zanamivir.
Teeft :
- Active metabolite, Acute influenza, Adverse effects, Adverse events, Amantadine, Amantadine hydrochloride, Antibiotic, Antimicrob, Antimicrob agents chemother, Antimicrobial agents, Antiviral, Antiviral activity, Antiviral drug resistance, Available agents, Available neuraminidase inhibitors, Bioavailability, Chemother, Clin, Clin pharmacokin, Clinical pharmacokinetics, Clinical trials, Combination therapy, Concomitant vaccination, Control subjects, Creatinine clearance, Drug interactions, Elderly nursing home residents, Excellent overview, Febrile patients, Global neuraminidase inhibitor susceptibility network, Glomerular filtration, Guanosine analog, Hayden, Healthy adults, Healthy volunteers, Hemagglutinin, Household contacts, Illness duration, Immunocompromised, Immunocompromised child, Immunocompromised hosts, Important differences, Infectious diseases, Influenza, Influenza hayden, Influenza infections, Influenza virus, Influenza viruses, Inhaled, Inhaled zanamivir, Inhibitor, Interscience conference, Largest study, Median time, Moderate nausea, Neuraminidase, Neuraminidase inhibitor resistance, Neuraminidase inhibitor zanamivir, Neuraminidase inhibitors, Normal activity, Oral administration, Oral oseltamivir, Oral oseltamivir treatment, Oseltamivir, Oseltamivir carboxylate, Overview, Placebo, Placebo days, Plasma elimination, Plasma protein binding, Pregnant women, Pulmonary disease, Randomized, Regimen findings, Relief medications, Renal impairment, Representative studies, Resistant virus, Respiratory tract, Respiratory tract complications, Ribavirin, Ribavirin triphosphate, Rimantadine, September toronto, Serious toxicity, Several studies, Severe influenza, Significant drug interactions, Symptom, Symptom alleviation, Symptoms days, Therapeutic effectiveness, Therapeutic efficacy, Therapeutic options, Tuberculosis chest, Tubular secretion, Uncomplicated influenza, Usual activities, Usual activity, Viral, Viral neuraminidase, Virus infection, Virus infections, Virus strain numbers, Years inhaled, Zanamivir, Zanamivir treatment studies.

Abstract

Abstract: Over the past few years a novel class of antiviral agents, the neuraminidase inhibitors, has been found to be safe and effective in the prevention and treatment of influenza. Previously available agents, the M2 inhibitors amantadine and rimantadine, could only be used to treat influenza A infections and resistance develops rapidly. Zanamivir (Relenza®) and oseltamivir (Tamiflu™), the two clinically available neuraminidase inhibitors, are effective for treating both influenza A and B infections in adults and children and have also been shown to reduce the frequency of antibiotic-requiring complications of influenza infections. Inhaled zanamivir has shown benefit in treating acute influenza with mild to moderate underlying asthma or chronic obstructive pulmonary disease. Studies are needed to examine the use of these agents, alone or in combination with M2 inhibitors or ribavirin, in the management of severe infections in hospitalized patients and immunocompromised hosts. Studies are also needed to address other groups at increased risk for influenza complications, such as pregnant women and children below one year of age.

Url:

https://api.istex.fr/ark:/67375/6H6-2R3399BL-9/fulltext.pdf

DOI: 10.1016/S1471-4892(01)00084-4

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 000A21
to stream Istex, to step Curation: 000A21
to stream Istex, to step Checkpoint: 000681
to stream Main, to step Merge: 001894
to stream Main, to step Curation: 001854

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic options for the management of influenza</title>
<author><name sortKey="Ison, Michael G" sort="Ison, Michael G" uniqKey="Ison M" first="Michael G" last="Ison">Michael G. Ison</name>
</author>
<author><name sortKey="Hayden, Frederick G" sort="Hayden, Frederick G" uniqKey="Hayden F" first="Frederick G" last="Hayden">Frederick G. Hayden</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E322701CE07DFA8A0DF19075A00CA8FD6F0E9CA4</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1016/S1471-4892(01)00084-4</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-2R3399BL-9/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000A21</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A21</idno>
<idno type="wicri:Area/Istex/Curation">000A21</idno>
<idno type="wicri:Area/Istex/Checkpoint">000681</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000681</idno>
<idno type="wicri:doubleKey">1471-4892:2001:Ison M:therapeutic:options:for</idno>
<idno type="wicri:Area/Main/Merge">001894</idno>
<idno type="wicri:Area/Main/Curation">001854</idno>
<idno type="wicri:Area/Main/Exploration">001854</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapeutic options for the management of influenza</title>
<author><name sortKey="Ison, Michael G" sort="Ison, Michael G" uniqKey="Ison M" first="Michael G" last="Ison">Michael G. Ison</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Virginie</region>
</placeName>
<wicri:cityArea>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville</wicri:cityArea>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Hayden, Frederick G" sort="Hayden, Frederick G" uniqKey="Hayden F" first="Frederick G" last="Hayden">Frederick G. Hayden</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Virginie</region>
</placeName>
<wicri:cityArea>University of Virginia Health Sciences Center, Division of Infectious Diseases, Charlottesville</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Current Opinion in Pharmacology</title>
<title level="j" type="abbrev">COPHAR</title>
<idno type="ISSN">1471-4892</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="2001">2001</date>
<biblScope unit="volume">1</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="482">482</biblScope>
<biblScope unit="page" to="490">490</biblScope>
</imprint>
<idno type="ISSN">1471-4892</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1471-4892</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine</term>
<term>Influenza</term>
<term>M2 Inhibitor</term>
<term>Neuraminidase inhibitor</term>
<term>Oseltamivir</term>
<term>Pharmaceutical Science</term>
<term>Pharmacology</term>
<term>Ribavirin</term>
<term>Rimantadine</term>
<term>Virology</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Active metabolite</term>
<term>Acute influenza</term>
<term>Adverse effects</term>
<term>Adverse events</term>
<term>Amantadine</term>
<term>Amantadine hydrochloride</term>
<term>Antibiotic</term>
<term>Antimicrob</term>
<term>Antimicrob agents chemother</term>
<term>Antimicrobial agents</term>
<term>Antiviral</term>
<term>Antiviral activity</term>
<term>Antiviral drug resistance</term>
<term>Available agents</term>
<term>Available neuraminidase inhibitors</term>
<term>Bioavailability</term>
<term>Chemother</term>
<term>Clin</term>
<term>Clin pharmacokin</term>
<term>Clinical pharmacokinetics</term>
<term>Clinical trials</term>
<term>Combination therapy</term>
<term>Concomitant vaccination</term>
<term>Control subjects</term>
<term>Creatinine clearance</term>
<term>Drug interactions</term>
<term>Elderly nursing home residents</term>
<term>Excellent overview</term>
<term>Febrile patients</term>
<term>Global neuraminidase inhibitor susceptibility network</term>
<term>Glomerular filtration</term>
<term>Guanosine analog</term>
<term>Hayden</term>
<term>Healthy adults</term>
<term>Healthy volunteers</term>
<term>Hemagglutinin</term>
<term>Household contacts</term>
<term>Illness duration</term>
<term>Immunocompromised</term>
<term>Immunocompromised child</term>
<term>Immunocompromised hosts</term>
<term>Important differences</term>
<term>Infectious diseases</term>
<term>Influenza</term>
<term>Influenza hayden</term>
<term>Influenza infections</term>
<term>Influenza virus</term>
<term>Influenza viruses</term>
<term>Inhaled</term>
<term>Inhaled zanamivir</term>
<term>Inhibitor</term>
<term>Interscience conference</term>
<term>Largest study</term>
<term>Median time</term>
<term>Moderate nausea</term>
<term>Neuraminidase</term>
<term>Neuraminidase inhibitor resistance</term>
<term>Neuraminidase inhibitor zanamivir</term>
<term>Neuraminidase inhibitors</term>
<term>Normal activity</term>
<term>Oral administration</term>
<term>Oral oseltamivir</term>
<term>Oral oseltamivir treatment</term>
<term>Oseltamivir</term>
<term>Oseltamivir carboxylate</term>
<term>Overview</term>
<term>Placebo</term>
<term>Placebo days</term>
<term>Plasma elimination</term>
<term>Plasma protein binding</term>
<term>Pregnant women</term>
<term>Pulmonary disease</term>
<term>Randomized</term>
<term>Regimen findings</term>
<term>Relief medications</term>
<term>Renal impairment</term>
<term>Representative studies</term>
<term>Resistant virus</term>
<term>Respiratory tract</term>
<term>Respiratory tract complications</term>
<term>Ribavirin</term>
<term>Ribavirin triphosphate</term>
<term>Rimantadine</term>
<term>September toronto</term>
<term>Serious toxicity</term>
<term>Several studies</term>
<term>Severe influenza</term>
<term>Significant drug interactions</term>
<term>Symptom</term>
<term>Symptom alleviation</term>
<term>Symptoms days</term>
<term>Therapeutic effectiveness</term>
<term>Therapeutic efficacy</term>
<term>Therapeutic options</term>
<term>Tuberculosis chest</term>
<term>Tubular secretion</term>
<term>Uncomplicated influenza</term>
<term>Usual activities</term>
<term>Usual activity</term>
<term>Viral</term>
<term>Viral neuraminidase</term>
<term>Virus infection</term>
<term>Virus infections</term>
<term>Virus strain numbers</term>
<term>Years inhaled</term>
<term>Zanamivir</term>
<term>Zanamivir treatment studies</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Pharmacologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Over the past few years a novel class of antiviral agents, the neuraminidase inhibitors, has been found to be safe and effective in the prevention and treatment of influenza. Previously available agents, the M2 inhibitors amantadine and rimantadine, could only be used to treat influenza A infections and resistance develops rapidly. Zanamivir (Relenza®) and oseltamivir (Tamiflu™), the two clinically available neuraminidase inhibitors, are effective for treating both influenza A and B infections in adults and children and have also been shown to reduce the frequency of antibiotic-requiring complications of influenza infections. Inhaled zanamivir has shown benefit in treating acute influenza with mild to moderate underlying asthma or chronic obstructive pulmonary disease. Studies are needed to examine the use of these agents, alone or in combination with M2 inhibitors or ribavirin, in the management of severe infections in hospitalized patients and immunocompromised hosts. Studies are also needed to address other groups at increased risk for influenza complications, such as pregnant women and children below one year of age.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Virginie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Virginie"><name sortKey="Ison, Michael G" sort="Ison, Michael G" uniqKey="Ison M" first="Michael G" last="Ison">Michael G. Ison</name>
</region>
<name sortKey="Hayden, Frederick G" sort="Hayden, Frederick G" uniqKey="Hayden F" first="Frederick G" last="Hayden">Frederick G. Hayden</name>
<name sortKey="Ison, Michael G" sort="Ison, Michael G" uniqKey="Ison M" first="Michael G" last="Ison">Michael G. Ison</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001854 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001854 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:E322701CE07DFA8A0DF19075A00CA8FD6F0E9CA4
   |texte=   Therapeutic options for the management of influenza
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Therapeutic options for the management of influenza

Therapeutic options for the management of influenza

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri